{
  "id": 7420808,
  "title": "Progyny director Kevin Gordon sells $321,358 in company stock",
  "url": "https://urgent.news/2026/09/14/progyny-director-kevin-gordon-sells-321-358-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-14T23:01:04.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/progyny-director-kevin-gordon-sells-321358-in-company-stock-93CH-4900657"
  },
  "original_language": "en",
  "account": null,
  "summary": "Progyny director Kevin Gordon sold 11,500 shares of the company's stock on September 10, 2026, for a total of $321,358, according to Investing.com. This sale occurred after the stock had surged 59% over the previous six months, though it remains undervalued according to InvestingPro's analysis, which suggests a price target of $33.00 per share with a Market Outperform rating. Despite the insider sale, Progyny reported strong second-quarter results for 2026, exceeding analyst expectations with adjusted earnings of $0.55 per share and revenue of $350.51 million. The company also announced a partnership with CalPERS and is expanding its addressable market through a new pooled risk, fixed premium offering.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}